Zinc deficiency and oxidative stress in brain: Magnetic resonance investigations in weanling rats

2004 ◽  
Vol 17 (3) ◽  
pp. 161-174 ◽  
Author(s):  
Rheal A. Towner ◽  
Christopher Appleby ◽  
Mark Levy ◽  
Tammy M. Bray
2019 ◽  
Vol 38 (03) ◽  
pp. 191-204 ◽  
Author(s):  
D. Lazarova ◽  
S. Shibata ◽  
I. Ishii ◽  
G. Zlateva ◽  
Z. Zhelev ◽  
...  

2017 ◽  
Vol 179 (1) ◽  
pp. 102-109 ◽  
Author(s):  
Nematollah Ahangar ◽  
Maloos Naderi ◽  
Abdolali Noroozi ◽  
Maryam Ghasemi ◽  
Ehsan Zamani ◽  
...  

Nutrients ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1680
Author(s):  
Shinya Nakatani ◽  
Katsuhito Mori ◽  
Tetsuo Shoji ◽  
Masanori Emoto

Deficiency of the micronutrient zinc is common in patients with chronic kidney disease (CKD). The aim of this review is to summarize evidence presented in literature for consolidation of current knowledge regarding zinc status in CKD patients, including those undergoing hemodialysis. Zinc deficiency is known to be associated with various risk factors for cardiovascular disease (CVD), such as increased blood pressure, dyslipidemia, type 2 diabetes mellitus, inflammation, and oxidative stress. Zinc may protect against phosphate-induced arterial calcification by suppressing activation of nuclear factor kappa light chain enhancer of activated B. Serum zinc levels have been shown to be positively correlated with T50 (shorter T50 indicates higher calcification propensity) in patients with type 2 diabetes mellitus as well as those with CKD. Additionally, higher intake of dietary zinc was associated with a lower risk of severe abdominal aortic calcification. In hemodialysis patients, the beneficial effects of zinc supplementation in relation to serum zinc and oxidative stress levels was demonstrated in a meta-analysis of 15 randomized controlled trials. Thus, evidence presented supports important roles of zinc regarding antioxidative stress and suppression of calcification and indicates that zinc intake/supplementation may help to ameliorate CVD risk factors in CKD patients.


2011 ◽  
Vol 29 ◽  
pp. e370
Author(s):  
C. Arranz ◽  
S. Aguirre ◽  
L. Savignano ◽  
D. Cardelli Alcalde ◽  
F. Mendes Garrido ◽  
...  

2015 ◽  
Vol 54 ◽  
pp. 84-92 ◽  
Author(s):  
Zeynep Bostanci ◽  
Ronald P. Mack ◽  
Sooyeon Lee ◽  
David I. Soybel ◽  
Shannon L. Kelleher

2009 ◽  
Vol 8 (3) ◽  
pp. 7290.2009.00017 ◽  
Author(s):  
Albrecht Stroh ◽  
Johannes Boltze ◽  
Katharina Sieland ◽  
Katharina Hild ◽  
Cindy Gutzeit ◽  
...  

Magnetic resonance imaging (MRI) of magnetically labeled stem cells has become a valuable tool in the understanding and evaluation of experimental stem cell–based therapies of degenerative central nervous system disorders. This comprehensive study assesses the impact of magnetic labeling of both human and rodent stem cell–containing populations on multiple biologic parameters as maintenance of stemness and oxidative stress levels. Cells were efficiently magnetically labeled with very small superparamagnetic iron oxide particles. Only under the condition of tailored labeling strategies can the impact of magnetic labeling on vitality, proliferation, pluripotency, and oxidative stress levels be minimized. In a rat model of Parkinson disease, magnetically labeled mouse embryonic stem cells were tracked by high-field MRI for 6 months. Significant interindividual differences concerning the spatial distribution of cells became evident. Histologically, transplanted green fluorescent protein–positive iron oxide–labeled cells were clearly identified. No significant increase in oxidative stress levels at the implantation site and no secondary uptake of magnetic label by host phagocytotic cells were observed. Our study strongly suggests that molecular MRI approaches must be carefully tailored to the respective cell population to exert minimal physiologic impact, ensuring the feasibility of this imaging approach for clinical applications.


Sign in / Sign up

Export Citation Format

Share Document